Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: violatrader who wrote (48266)	7/2/1999 1:42:00 PM
From: bobby is sleepless in seattle	Read Replies (1) \| Respond to of 120523

lcav...been following for over a year, entered in 4's and reestablished another trading position just recently accumulating from 8-9 5/16..."eye" happen to be very bullish on this sector...pardon the feeble attempt at the pun... here's a perpective regarding intacs (kera)...might give a snapshot on the industry as a whole and perhaps potential competition laser surgery faces... ragingbull.com luck to both of us although I highly doubt we'll need it...

To: violatrader who wrote (48266)	7/2/1999 1:45:00 PM
From: Burjis S.	Read Replies (2) \| Respond to of 120523

Vee.... The only negative on this stock is that PRU gave it a blessing! <ggg> my experience has been whenever Pru does that to any of the stocks I have owned they have always died short term, maybe this will be a turn around case. Of the Laser Vision stocks, I like BEAM SNRS and VISX in that order, I just bought some Sept 20 calls and stock in BEAM at 19.31 about 2 weeks ago the stock did got to 22+ but has retraced here, this next month is going to be good for this stock as it has great potential and is the maker of the system and it owns Lens Care from where it gets it's customer base. SNRS has a new technology and if approved by the FDA could make a substantial gain in the future. The Ophthalmic Devices Advisory Panel will review the Company's Premarket Approval (PMA) application on July 22, 1999 for the treatment of hyperopia (+.75 to +2.50 diopters). Sunrise believes about 31% of Americans over 40 have hyperopia from +.75 to +2.50 diopters. VISX has already had a huge run up but is the leader of the pack. Best wishes, Burjis